Share Twitter LinkedIn Facebook Email Andrzej Jakubowiak, MD Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, discusses GRIFFIN Study Outcomes. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read